Small Molecule Therapeutics
The Power of Small Molecules and its Potential Targets.
Many small molecules can work as therapeutic agents. Novel synthetic compounds and endogenous molecules, such as metabolites, can influence biology by modifying its availability within a cell. New and effective molecular therapeutics capitalize on these findings and are being further developed at UMassMed. In addition, there is research into identifying the critical molecular targets that may enable further discoveries of therapeutic targets.
Browse Our Small Molecule Therapeutics Inventions:
Title: Lanatoside C Inhibition of Zika Virus Infection. UMMS16-60; Patent Pending.
This new discovery has found that cardiac glycoside Lanatoside C - an inhibitor of dengue virus, flavivirus Kunjin, alphavirus Chickingunya, and enterovirus 71 - also effectively stops replication of the Zika virus. This invention discloses treatment of Zika virus with Lanatoside C alone and in combination with ribavirin or ivermectin.
Title: Topical Application of Agents to Affect Neutrophil Migration Across Polarized Epithelial Barriers. UMMS16-46; Patent Pending.
A newly discovered efflux pump, MRP2, secretes lipids that attract neutrophils and initiate inflammation. Inhibition of MRP2 or inactivation of the secreted lipids can safely and effectively reduce inflammation at local tissues. This invention reduces inflammation by opposing the pro-inflammatory MRP2 system also by utilizing an endocannabinoid system that acts through the CB2 receptor. Increasing the activity of the CB2 endocannabinoid pathway can suppress local neutrophil migration consequentially result in anti-inflammation.
Title: Anthelmintic Compositions and Methods. UMMS16-43; Patent Pending.
Title: A New Generation of Antihelminthic Medications that Trigger Aberrant Immune Responses in Pathogenic Nematodes. UMMS16-25; Patent Pending.
The present invention is related to the treatment and prevention of nematode infection in mammals. In general, the present invention provides small organic compounds and RNAi molecules targeting the p38 mitogen activated protein kinase pathway in xenobiotic-resistant nematodes. Further, the present invention combines an immunostimulatory small molecule with a pharmacologic inducer of an endoplasmic reticulum unfolded protein response to provide a synergistic therapy for human pathogenic nematode infection.
Title: Identification of Epigenetic Modifiers of the Silenced FMR1 Gene: Potential Targets for Fragile X Syndrome Therapeutics. UMMS16-03; Patent Pending.
This invention comprises methods for treating Fragile X Syndrome and other FMR1-inactivation-associated disorders by inhibiting epigenetic silencers of the FMR1 gene. The invention discloses a variety of FMR1 modulators, functioning either through RNA interference or small molecule inhibition, for optimal FMR1 reactivation.
Title: Improving Efficacy of VEGF-Targeted Therapy in Prostate Cancer. UMMS16-02; Patent Pending.
Back To Top
Title: New XCI Inhibitors as Potential Rett Syndrome Therapeutics. UMMS15-53; Patent Pending.
This invention provides methods of treating a subject having a dominant X-linked disease, the method comprising administering to the subject an X chromosome inactivation factor (XCIF) inhibitor in an amount effective for inducing expression a target X-linked gene. The invention provides small molecule and oligonucleotide XCIF inhibitors. In some embodiments, the X-linked gene is MECP2 and the X-linked disease is Rett Syndrome.
- Inventor: Michael R Green
- Applications: Rett Syndrome, Hypophosphatemia, Incontinentia pigmenti, Aicardi, CHILD syndrome, Dermal hypoplasia, Lujan-Fryns syndrome, Nephritis, Fragile X syndrome/Fragile X-associated tremor/ataxia syndrome, Charcot-Marie-Tooth disease, Myopathy, Dysplasia
Title: Targeting GDF6 and BMP Signaling for Anti-cancer Therapy. UMMS15-21; Patent Pending.
Title: Hedgehog Signaling in Bipolar Affective Disorder. UMMS15-02; Patent Pending. Related Publication.
The invention encompasses methods of treating psychiatric affective disorders by administering to the subject a therapeutically effective amount of an antagonist to Smoothened (Smo), an antagonist to Patched-1 (Ptch-1) and/or an antagonist to Sonic Hedgehog. The invention further provided methods for diagnosing affective disorders.
- Inventors: Marzena Galdzicka, Edward I Ginns
- Applications: Psychiatry/Psychiatric disorder, ADD/ADHD, Bipolar affective disorder (BPAD), Smith-Lemli-Opitz syndrome, Affective disorder, Anxiety, Autism, Mental health, Mood disorder, Obsessive-compulsive disorder (OCD)
Back To Top
Title: Novel Neisseria Gonorrhoeae Therapeutic Based on CMP-nonulosonate Sugars. UMMS14-77; Patent Pending.
Invention encompasses a new strategy to combat drug-resistant gonorrhea. This technology manipulates the lipooligosacchride capping of gonococci, thereby decreasing it’s fitness and virulence. By interrupting the sialic acid mediated pathogenesis that contributes to drug-resistance, this intervention can render gonorrhoeae sensitive to killing by the innate immunity system.
Title: A Method to Treat Chronic Myelogenous Leukemia (CML) Patients who have Developed BCR-ABL-Independent Imatinib Resistance and to Eradicate CML Stem Cells. UMMS14-47; Patent Pending.
This new innovation addresses the issues associated drug resistance of chronic myeloid leukiemia (CML) cells to imatinib mesylate (IM). IM improves patient survival and are used widely to treat early stages of CML, but the efficacy is known to drop when drug resistance is developed. This new invention builds on the finding that in IM resistant CML cells, RAF/MEK/ERK pathway is activated that is not subjected to IM targeting. Remarkably, when FDA approved MEK inhibitor, trametinib is treated in conjunction with IM, they synergistically kill CML cells and improve survival in mouse models.
Title: Surface Mineralization of Metal Alloys Grafted With Zwitterionic Polymer Brushes. UMMS14-36; Patent Pending.
The invention provides a novel approach to hydrogels with predictable degradation/gelling kinetics, which is useful for many biomedical applications where appropriate gelling kinetics and the timely disintegration of the hydrogel (e.g., drug delivery, guided tissue regeneration) is required. Precisely controlling hydrogel degradation over a broad range in a predictable manner is achieved via a simple but versatile hydrogel platform that allows formulation of hydrogels with predictable disintegration time from within 2 days to >250 days yet comparable macroscopic physical properties.
Title: Alkylated Amphiphilic Polymer Networks for Bioactive Lipid Delivery. UMMS14-16; Patent Pending.
The invention provides unique amphiphilic polymers may be employed as controlled delivery vehicles or tissue engineering scaffolds wherein the delivery of lipophilic or amphiphilic bioactive molecules can be achieved. An amphiphilic biodegradable polymer platform is disclosed herein for the stable encapsulation and sustained release of biomolecules, such as phospholipid spingosine 1-phosphate (SIP) which can be used to promote angiogenesis alone or in conjunction with VEGF.
Back To Top
Title: Compositions and Methods for Recruitment and Activation of Macrophages in Injured Tissues and in Implanted Biomaterials Used for Tissue Engineering. UMMS13-62; Patent Pending.
The present invention is related to the field of wound healing and regeneration and repair of injured internal tissues and tissue engineering by synthetic implants and implants of natural origin. In particular, the present invention provides compositions and methods comprising molecules (such as nanoparticles) with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue, and rapid localized recruitment and activation of macrophages that promote regeneration and repair of a wide variety of internal tissues and organs injured as a result of various types of trauma as well as of tissues and organs treated with biomaterials.
Title: Construction of a Trifunctional and Completely Clearable Specific Targeting Agent. UMMS13-45; Patent Pending.
Back To Top
Back To Top
Title: Modulation of Ubiquitination of Synaptic Proteins for the Treatment of Neurodegenerative and Psychiatric Disorders. UMMS11-03; Patent Pending.
This invention is a potential therapeutic for neurological and psychiatric disorders in which increased cell surface expression of AMPA, NMDA, and D1 dopamine receptors is desired. This technology is based on the discovery that inhibition of PSD-95, Mdm2, or Mdm4 decreases endocytosis of glutamate, NMDA, and dopamine receptors thereby modulating synaptic plasticity. The invention further provides screens for additional therapeutic agents targeting Mdm2, Mdm4, and PSD-95.
Back To Top
Title: Arylthiazolyl Piperidines as Modulators of Survival Motor Neuron (SMN) Production. UMMS10-63; Patent Pending.
This invention discloses aryl substituted thiazol-2-yl-piperidines and other related compounds that modulate production of the protein, Survival Motor Neuron (SMN), that plays a role in the treatment of spinal muscular atrophy. These newly identified compounds can modulate SMN2 protein levels and ultimately increase motor neuron survival. Pharmacological composition and methods for treating spinal muscular atrophy are further shown.
Title: SULFONATE COMPOUNDS. UMMS10-48; Patent 9,329,185
This invention provides a new chemically-stable platform for delivering hydrophobic molecules in to cell cytoplasm. Sulfonates are used to impart water-solubility to hydrophobic molecules but does not readily cross cellular membrane to access cellular compartments. Thus, the TFA-labile sulfonate protection group helps to overcome the difficulty in delivering hydrophobic molecules to the intracellular environment. Currently existing protection molecules are complicated and expensive to produce while it also requires additional steps to remove its byproducts after TFA mediated deprotection. This new invention TFMB sulfonate esters are unique because they are 1) stable to nucleophilic attack (e.g. sodium iodide and piperidine), 2) synthesized in one step from commercially-available materials, and 3) easily removable with pig liver esterase (~2min). This new UMass Medical School sulfate protection group provides new opportunities for research molecule delivery of hydrophobic drugs to mammalian cells.
Title: A New Approach to Accelerate Antibiotic Action. UMMS10-30; Patent Pending.
This is a novel method to increase the efficacy of antibiotics by targeting bacterial central metabolism. The UMass Medical School inventors identified 38 metabolic targets, inhibition of which with concurrent antibiotic treatment can synergistically kill slow-growing dormant Mycobacterium tuberculosis (Mtb), the agent of human tuberculosis. These slow-growing bacterial populations are challenging to eradicate because they are refractory to antibiotic treatment. Inhibiting Mtb central metabolism enables more thorough treatment of tuberculosis infection and may be applicable to other infectious diseases.
Title: YEAST CELL WALL PARTICLES FOR RECEPTOR-TARGETED NANOPARTICLE DELIVERY. UMMS10-29; Patent 9,242,857
The present invention improves upon previously described yeast-based microencapsulation methodologies, in particular, by providing for the incorporation of nanoparticles into and/or onto yeast cell wall particles (YCWPs), for example, yeast glucan particles (microparticles) (YGPs). The improved technologies provide for delivery of nanoparticles, the nanoparticles themselves having utility in biomedical applications, or the nanoparticles imparting one or more functionalities of use in various biomedical, e.g., drug delivery applications.
Title: METHODS AND COMPOSITIONS TO REDUCE OXIFAATIVE STRESS. UMMS10-19; Patent 9,089,573
This patented technology discloses pharmaceutical compositions consisting of L-argnine, tetrahydrobiopterin, and ascorbate to treat diseases of oxidative stress and improve the therapeutic properties of stem cells.
Title: METHODS FOR TREATING GLIOBLATOMA. UMMS10-06; Patent 8,637,493
Described are methods for treating glioblastoma by administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. Specifically provided are methods of administering to the subject a therapeutically effective amount of temozolomide and a gamma secretase inhibitor.
Title: Immunotherapy for T Cell-Mediated Autoimmune Diseases Using ITK Inhibitors. UMMS10-05; Patent Pending.
The present disclosure is based, in part, on the discovery that interleukin-2-inducible T cell kinase (ITK) and CD28 signals regulate auto-reactive T cell trafficking and that organ-specific T cell mediated autoimmune diseases such as Type 1 diabetes and multiple sclerosis. Accordingly, the present specification provides methods of treating organ-specific T cell mediated autoimmune diseases by inhibiting ITK with a therapeutically effective amount of an ITK inhibitor, e.g., BMS509744, ibrutinib, 10n, 2-amino-5-(thioaryl)thiazole, 5 aminomethylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene.
Title: Gamitrinibs Sensitize Cancer Cells to TRAIL-Mediated Cell Death. UMMS10-01; Patent Pending.
This novel technology describes methods to enhance apoptosis via mitochondria-targeted anti-tumor agents, death receptor agonists, autophagy inhibitors, and NF-κB signaling pathway inhibitors, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.
Back To Top
Title: Identification of Genes Preferentially Required for Growth of p53-Deficient Human Cancer Cells. UMMS09-56; Patent Pending.
This invention discloses a novel cluster of genes discovered through a RNAi screen which could be a potential target of cancer treatment in p53 mutation cancers. p53 gene is mutated in numerous cancer therefore the newly discovered genes have potential for becoming a therapeutic target in wide range of cancers. The inventors performed a bias screen using p53 mutant cancer cells, p53-/- and +/- colorectal HCT116 cell lines and shRNA library. This screening yielded a selection of genes that are preferentially required for viability in p53 mutant cancer cells. The verification experiments showed that a 24 gene-knockdown preferentially impaired growth of the p53 cell line. Using mice xenograft, 4 required genes were identified and show high potential for clinical use.
Title: COMPOUNDS FOR MODULATING TLR2. UMMS09-52 Patent 8,609,663; 9,271,972
Viral infection causes damage to the host via stimulation of production of host cytokines. These processes can culminate in edema and damage to host organs. From screening, this novel invention identifies molecules that could potentially inhibit the cytokine response to viral infection by inhibiting RNA virus-mediated TNF-alpha production. The current invention discloses methods of the system used to screen, a TLR2 and CD14 stable cell line, and molecular inhibitors of Lymphocytic Choriomeningitis Virus (LCMV) induced cytokine production. These newly discovered molecules may facilitate amelioration of symptoms in a broad range of hemorrhagic fever viruses.
- Inventors: Robert W Finberg, Shenghua Zhou, Evelyn A Kurt-Jones
- Technology: Small Molecules, Biologics
- Applications: Cell line, High throughput screening, Virology, Infectious Disease, Immunology, Immune edema, Hemorrhagic fever, Lymphocytic Choriomeningitis Virus (LCMV)
- Patent Expiration Date: 2031-04-01; Active
Title: COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR. UMMS09-45; Patent 8,377,639, 8,962,244
Title: A Candida Albicans Mutant Strain and an Enzymatic Assay and for the Development of Antifungal Drugs. UMMS09-34; Patent Pending.
Title: COMPLEMENT FACTOR H-BASED ASSAYS FOR SERUM BACTERICIDALACTIVITY AGAINST NEISSERIA MENINGITIDIS. UMMS09-17; Patent 8,476,032
This invention discloses an assay method for detecting anti-Neisseria antibodies. Human factor H (fH) is a virulence factor that helps Neisseria to resist complement-mediated killing, thus circumventing the host’s innate immune response. Higher serum fH levels may correlate to patient susceptibility to infection. Neisserial factor H binding protein (fHBp) can be hindered by a human amino acid sequence revealed in the present technology, to facilitate accurate detection of Neisseria that exceeds the capability of existing methods. A reaction mixture containing bactericidal anti-Neisseria antibodies, a fH polypeptide comprising an amino acid sequence of human Short Consensus Repeat 6 sources of non human complement (SCR), and a Neisseria bacterium. This invention additionally discloses an animal model of Neisseria infection.
Title: INTRACELLULAR DNA RECEPTOR. UMMS09-11; Patent 8,334,101
The innate immune system recognizes non-self genetic material and mounts a defensive immune response. However, self cytosolic DNA at times gets targeted and the process by which this phenomenon occurs has been largely unknown. The inventors have discovered PISA (PYHIN protein stimulating ASC), a receptor found to be necessary for activation of the ACS/caspase-1 axis of innate immunity in response to recognition of self cytosolic DNA. This invention discloses methods for identification and compounds found to modulate the PISA receptor and it’s downstream immune response.
Title: METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIE. UMMS09-08; Patent 9,475,864
Title: RESPIRATORY SYNCTIAL VIRUS (RSV) SEQUENCES FOR PROTEIN EXPRESSION AND VACCINES. UMMS09-03; Patent 8,580,270; 9,168,294
This invention discloses a sequence of efficient cleavage point of F protein, of the respiratory syncytial virus (RSV) that causes infection. The cDNA has an optimized codon of F protein, which may be useful for developing a more effective RSV vaccine.
Back To Top
Title: Co-evolved Protease Substrate Cleavage Site Mutations Enhance Protease Inhibitor Resistance. UMMS08-59; Patent Pending.
This new invention predicates on the finding that drug resistance in HIV arises from evolution of HIV proteases and it’s associated substrates, and discloses mutation patterns of both proteases and substrates that can be used to predict the efficacy of particular therapy in HIV patients. Understanding these mutational combinations will greatly change the approach to optimizing a patient-centered approach to managing HIV therapy.
Title: Kratom and its Alkaloidal Components as Therapy for Withdrawal from Prescription Opioid Pharmaceuticals. UMMS08-53; Patent Pending.
This invention utilizes natural products derived from Kratom, a medicinal herb native to Thailand, to treat opioid withdrawal from prescription opioid agents. Mitragynine is the predominant alkaloid isolated from Kratom and has been found to bind to opioid receptors. This finding suggests a mechanism by which Kratom and its derived molecules may reduce opioid craving. These findings introduce a novel potential for the development of a naturally derived agent for the treatment and management of opioid addiction and withdrawal.
Title: Use of Cathepsin B Inhibitors for the Treatment of IL-1 Related Diseases. UMMS08-51; Patent Pending.
This innovation describes detailed mechanisms of how immune cells recognize microorganisms (non-self) from host (self). The cytoplasmic receptor complex NALP3 inflammasome has been found to react to a variety of crystals such as silica crystals or cholesterol crystals, all of which were found to require phagocytosis for activation. By inhibiting phagosomal acidification, the inventors were able to prevent activation of NALP3 in the presence of the crystal activators. Understanding these mechanisms may be valuable to research into IL-1 related diseases of sterile inflammation including atherlosclerosis, amyloidosis, Alzheimer silicosis, asbestosis and others.
Title: HIV-1 Protease Inhibitors: Part 6. UMMS08-41.
This invention provides new therapeutic agents to treat HIV using protease inhibitors that are less prone to resistance stemming from drug resistant mutations. Using computational and organic chemistry techniques, the inventors designed these new molecules by carefully considering nature of the HIV protease and it’s ability to detect substrates. This invention contains several sets of HIV protease inhibitors and unique drug combinations that have not yet been previously tested.
Title: WFS1: A Master Negative Regulator of Endoplasmic Reticulum Stress Signaling and an Effective Inducer of Insulin-Producing Cells. UMMS08-40; Patent Pending.
Title: MODULATION OF MIDBODY DERIVATIVES. UMMS08-18; Patent 9,409,978
- This new invention predicates on the finding that midbody (MB), a singular organelle formed between daughter cells during cytokinesis required for separation, are inherited asymeetrically by daughter cell of stem cells and cancer ‘stem cells’. The new methods disclosed in this invention can modulate degradation.
Title: Use of TRAIL Protein as Antiviral Agent. UMMS08-01; Patent Pending.
This new invention discloses an antiviral molecule, TRAIL, which reduces cellular antiviral effects, and may provide an opportunity for treatment of RNA virus infection. Blocking of TRAIL significantly reduces cellular antiviral effects, thus the invention proposes the use of TRAIL as therapy to reduce viral burden.